We are live on
!
Find out more
GCP
GSA Capital Partners Portfolio holdings
AUM
$1.59B
1-Year Est. Return
39.81%
This Fund
S&P 500
This Quarter
Est. Return
-17.67%
1 Year Est. Return
+39.81%
3 Year Est. Return
+94.75%
5 Year Est. Return
+73.44%
10 Year Est. Return
+404.29%
AUM
$666M
AUM Growth
-$78.6M
(-11%)
Cap. Flow
+$47.8M
Cap. Flow
% of AUM
7.17%
Top 10 Holdings %
Top 10 Hldgs %
3.73%
Holding
1,985
New
628
Increased
360
Reduced
345
Closed
644
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Relay Therapeutics
RLAY
|
+$3.83M |
| 2 |
iShares MSCI Emerging Markets ETF
EEM
|
+$3M |
| 3 |
Teck Resources
TECK
|
+$2.87M |
| 4 |
MODV
ModivCare
MODV
|
+$2.67M |
| 5 |
Genpact
G
|
+$2.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$3.07M |
| 2 |
CHS
Chicos FAS, Inc.
CHS
|
+$2.68M |
| 3 |
State Street SPDR S&P Regional Banking ETF
KRE
|
+$2.45M |
| 4 |
Crane NXT
CXT
|
+$2.44M |
| 5 |
ATCO
Atlas Corp.
ATCO
|
+$2.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.12% |
| 2 | Technology | 15.11% |
| 3 | Consumer Discretionary | 12.76% |
| 4 | Industrials | 12.53% |
| 5 | Financials | 11.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
776
Cue Biopharma
CUE
$114M
| $323K | 0.05% |
4,322
+1,103
| +34% | +$129K |
|
777
lululemon athletica
LULU
$14.6B
| $322K | 0.05% |
+1,181
| New | +$378K |
|
778
Mueller Industries
MLI
$15.2B
| $322K | 0.05% |
24,192
-22,796
| -49% | -$309K |
|
|
CIVI
779
DELISTED
Civitas Resources
CIVI
| $321K | 0.05% |
6,141
+1,657
| +37% | +$108K |
|
780
MP Materials
MP
$9.1B
| $321K | 0.05% |
+10,006
| New | +$404K |
|
|
DCT
781
DELISTED
Duck Creek Technologies, Inc. Common Stock
DCT
| $321K | 0.05% |
+21,596
| New | +$379K |
|
782
Brunswick
BC
$5.28B
| $320K | 0.05% |
+4,894
| New | +$360K |
|
783
Vicor
VICR
$10.2B
| $320K | 0.05% |
+5,848
| New | +$363K |
|
784
Ethan Allen Interiors
ETD
$603M
| $319K | 0.05% |
15,794
-25,565
| -62% | -$604K |
|
|
IMGO
785
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
| $319K | 0.05% |
+23,835
| New | +$378K |
|
786
Inspired Entertainment
INSE
$175M
| $318K | 0.05% |
36,881
+11,630
| +46% | +$119K |
|
|
SCU
787
DELISTED
Sculptor Capital Management, Inc. Class A Common Stock
SCU
| $318K | 0.05% |
38,082
-13,080
| -26% | -$144K |
|
788
Gates Industrial Corporation Ltd.
GTES
$7.15B
| $316K | 0.05% |
29,208
+12,155
| +71% | +$152K |
|
789
ImmunityBio
IBRX
$8.1B
| $316K | 0.05% |
84,884
+1,680
| +2% | +$6.75K |
|
|
KRON
790
DELISTED
Kronos Bio
KRON
| $316K | 0.05% |
86,846
+43,284
| +99% | +$196K |
|
791
JFrog
FROG
$10.8B
| $315K | 0.05% |
14,942
-10,372
| -41% | -$218K |
|
792
Federal Realty Investment Trust
FRT
$10.3B
| $314K | 0.05% |
+3,282
| New | +$368K |
|
793
Korro Bio
KRRO
$195M
| $314K | 0.05% |
4,185
-1,845
| -31% | -$125K |
|
794
Regeneron Pharmaceuticals
REGN
$80.8B
| $313K | 0.05% |
+530
| New | +$345K |
|
795
Life Time Group Holdings
LTH
$9.79B
| $312K | 0.05% |
+24,248
| New | +$346K |
|
796
Winnebago Industries
WGO
$909M
| $312K | 0.05% |
+6,433
| New | +$332K |
|
|
FUV
797
DELISTED
Arcimoto, Inc. Common Stock
FUV
| $312K | 0.05% |
4,770
+1,645
| +53% | +$130K |
|
798
Capital Southwest
CSWC
$1.6B
| $311K | 0.05% |
+16,866
| New | +$371K |
|
|
TBI
799
Trueblue
TBI
$311M
| $311K | 0.05% |
+17,369
| New | +$408K |
|
800
Tandem Diabetes Care
TNDM
$1.56B
| $311K | 0.05% |
5,261
+1,244
| +31% | +$102K |
|
Similar funds
NCL
DG
VNT
SS
GWANC
LCM
LCM
FDCP
GSA Capital Partners's Q2 2022 Portfolio in Review
As of Q2 2022, GSA Capital Partners held 1,985 positions worth $666M, down 11% from $745M the previous quarter. Its ten largest holdings account for 3.7% of the portfolio.
GSA Capital Partners deployed $47.8M of net new capital in Q2 2022, opening 628 new positions and adding to 360 existing holdings. Its largest new stake was Relay Therapeutics: 178,593 shares worth $2.99M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Chicos FAS, Inc., an estimated $2.68M trimmed.
- GSA Capital Partners's largest Q2 2022 buy was Relay Therapeutics: 178,593 shares worth $2.99M.
- GSA Capital Partners added most to Genpact in Q2 2022, an estimated $2.6M increase.
- GSA Capital Partners's biggest Q2 2022 reduction was Chicos FAS, Inc., cutting an estimated $2.68M.
- GSA Capital Partners fully exited Amazon in Q2 2022, selling an estimated $3.07M.
- GSA Capital Partners's ten largest holdings make up 3.7% of its $666M portfolio in Q2 2022.
- GSA Capital Partners opened 628 new positions and closed 644 in Q2 2022.
- GSA Capital Partners's portfolio value fell 11% quarter-over-quarter to $666M.
Based on GSA Capital Partners's 13F filing for Q2 2022, filed 9 Aug 2022.